Pharmacological treatments of COVID-19
Abstract The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Pharmacological reports - 72(2020), 6 vom: 20. Aug., Seite 1446-1478 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sahebnasagh, Adeleh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s43440-020-00152-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR042206251 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR042206251 | ||
| 003 | DE-627 | ||
| 005 | 20230519224018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201201s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-020-00152-9 |2 doi | |
| 035 | |a (DE-627)SPR042206251 | ||
| 035 | |a (SPR)s43440-020-00152-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Sahebnasagh, Adeleh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological treatments of COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pharmacology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV2 |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Avan, Razieh |e verfasserin |4 aut | |
| 700 | 1 | |a Saghafi, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Mojtahedzadeh, Mojataba |e verfasserin |4 aut | |
| 700 | 1 | |a Sadremomtaz, Afsaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Arasteh, Omid |e verfasserin |4 aut | |
| 700 | 1 | |a Tanzifi, Asal |e verfasserin |4 aut | |
| 700 | 1 | |a Faramarzi, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Negarandeh, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Safdari, Mohammadreza |e verfasserin |4 aut | |
| 700 | 1 | |a Khataminia, Masoud |e verfasserin |4 aut | |
| 700 | 1 | |a Rezai Ghaleno, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Habtemariam, Solomon |e verfasserin |4 aut | |
| 700 | 1 | |a Khoshi, Amirhosein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Heidelberg : Springer Nature, 1998 |g 72(2020), 6 vom: 20. Aug., Seite 1446-1478 |w (DE-627)SPR038875861 |w (DE-600)2129019-2 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2020 |g number:6 |g day:20 |g month:08 |g pages:1446-1478 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s43440-020-00152-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 72 |j 2020 |e 6 |b 20 |c 08 |h 1446-1478 | ||